


Maytansinol

Cat. No.:	HY-19474		
CAS No.:	57103-68-1		
Molecular Formula:	C ₂₈ H ₃₇ ClN ₂ O ₈		
Molecular Weight:	565.06		
Target:	Microtubule/Tubulin; ADC Cytotoxin; Apoptosis		
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 35 mg/mL (61.94 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.7697 mL	8.8486 mL	17.6972 mL
	5 mM	0.3539 mL	1.7697 mL	3.5394 mL
	10 mM	0.1770 mL	0.8849 mL	1.7697 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (3.68 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.68 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.68 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research^{[1][2]}.

In Vitro

Maytansinol (0.09-0.75 nM, 24 h) decreases the growth and survival of HCT116 cells in a dose-dependent manner^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

	<p>Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HCT116</td> </tr> <tr> <td>Concentration:</td> <td>0.09, 0.13, 0.18, 0.26, 0.37, 0.53, 0.75 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Reduced the growth and survival of HCT116 cells in a dose-dependent manner and the effect was more severe for p53+/+ than for p53-/- cells at both low and high doses. At intermediate doses, the effect was not significantly different on wild-type and p53 mutant cells.</td> </tr> </table>	Cell Line:	HCT116	Concentration:	0.09, 0.13, 0.18, 0.26, 0.37, 0.53, 0.75 nM	Incubation Time:	24 h	Result:	Reduced the growth and survival of HCT116 cells in a dose-dependent manner and the effect was more severe for p53+/+ than for p53-/- cells at both low and high doses. At intermediate doses, the effect was not significantly different on wild-type and p53 mutant cells.
Cell Line:	HCT116								
Concentration:	0.09, 0.13, 0.18, 0.26, 0.37, 0.53, 0.75 nM								
Incubation Time:	24 h								
Result:	Reduced the growth and survival of HCT116 cells in a dose-dependent manner and the effect was more severe for p53+/+ than for p53-/- cells at both low and high doses. At intermediate doses, the effect was not significantly different on wild-type and p53 mutant cells.								
In Vivo	<p>Maytansinol (2 μM, 10 μM, add to food, 1-2 h) can depolymerize microtubules in <i>Drosophila</i>. Maytansinol (0.5-2 μM, add to food, 10 days) decreases the survival rate of wild-type and p53 mutant larvae. Maytansinol (1 or 2 μM, add to food, 24-26 h) can induce apoptosis of wild-type <i>Drosophila</i> cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

REFERENCES

- [1]. Zafar S, et al. New insights into the anticancer therapeutic potential of maytansine and its derivatives. *Biomed Pharmacother.* 2023 Sep;165:115039.
- [2]. Edwards A, et al. Combinatorial effect of maytansinol and radiation in *Drosophila* and human cancer cells. *Dis Model Mech.* 2011 Jul;4(4):496-503.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA